CliffBio
small molecule

VASOPRESSIN

VASOPRESSIN

Loss of exclusivity—loss of exclusivity
CompanyEAGLE PHARMACEUTICALS INC

Drug detail

Brand nameVASOPRESSIN
Active ingredientVASOPRESSIN
Strength20UNITS/ML (20UNITS/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2021
Marketing statusDISCN

More from EAGLE PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VASOPRESSIN patent cliff — loss of exclusivity — | CliffBio